|
|
 Previous Article | Table of Contents | Next Article 
Predictive value for treatment outcome in acute myeloid leukemia of
cellular daunorubicin accumulation and P-glycoprotein expression
simultaneously determined by flow cytometry
A Guerci, JL Merlin, N Missoum, L Feldmann, S Marchal, F Witz, C Rose and O Guerci
Service de Medecine A. CHU Brabois, Vandoeuvre-les-Nancy, France.
To evaluate the clinical relevance of multidrug resistance (MDR) phenotype,
the intracellular daunorubicin accumulation (IDA) and P- glycoprotein
(P-gp) expression were investigated in 87 adult patients with acute
leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with
AML at relapse, and eight with secondary leukemia to myelodysplastic
syndromes (MDS-AML). IDA and P-gp expression were determined by
double-labeling flow cytometry analysis. Of 87 patients, 36 expressed P-gp
(41%). P-gp expression was more frequently observed in AML at relapse and
MDS-AML as compared with de novo AML (P = .0001). P-gp expression was
significantly associated with CD34 expression (P = .0003) and chromosome 7
abnormalities (P = .027). A significantly reduced IDA was observed in P-gp+
as compared with P-gp- patients (P = .0007). Of the 87 patients, 51
achieved complete remission (CR). A reduced IDA was observed in patients in
failure as compared with patients in CR (22% +/- 17% v 42% +/- 21%; P =
10(-4). Twelve of 36 P- gp+ patients as compared with 40 of 51 P-gp-
patients achieved CR (33% v 78%; P = 10(-4). The prognostic value of IDA
and P-gp expression was confirmed in multivariate analysis. These data
suggest that the determination of IDA and P-gp expression may be useful in
designing therapy for patients with AML.
Volume 85,
Issue 8,
pp. 2147-2153,
04/15/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Yokota, S. Kimura, S. Masuda, E. Ashihara, J. Kuroda, K. Sato, Y. Kamitsuji, E. Kawata, Y. Deguchi, Y. Urasaki, et al.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity
Blood,
January 1, 2007;
109(1):
306 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum, and D. E. Banker
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
Blood,
November 15, 2005;
106(10):
3584 - 3593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Qadir, K. L. O'Loughlin, S. M. Fricke, N. A. Williamson, W. R. Greco, H. Minderman, and M. R. Baer
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
Clin. Cancer Res.,
March 15, 2005;
11(6):
2320 - 2326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum, and D. E. Banker
The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin
Blood,
June 1, 2004;
103(11):
4276 - 4284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al.
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia
Blood,
August 15, 2003;
102(4):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Illmer, U. S. Schuler, C. Thiede, U. I. Schwarz, R. B. Kim, S. Gotthard, D. Freund, U. Schakel, G. Ehninger, and M. Schaich
MDR1 Gene Polymorphisms Affect Therapy Outcome in Acute Myeloid Leukemia Patients
Cancer Res.,
September 1, 2002;
62(17):
4955 - 4962.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. Baer, C. C. Stewart, R. K. Dodge, G. Leget, N. Sule, K. Mrozek, C. A. Schiffer, B. L. Powell, J. E. Kolitz, J. O. Moore, et al.
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Blood,
June 1, 2001;
97(11):
3574 - 3580.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. van den Heuvel-Eibrink, E. A. C. Wiemer, M. J. de Boevere, B. van der Holt, P. J. M. Vossebeld, R. Pieters, and P. Sonneveld
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia
Blood,
June 1, 2001;
97(11):
3605 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga
P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia
Clin. Cancer Res.,
August 1, 2000;
6(8):
3205 - 3214.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Pallis and N. Russell
P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway
Blood,
May 1, 2000;
95(9):
2897 - 2904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
